Fineline Cube

Follow:
14486 Articles
WuXi Biologics Reports 16.1% Revenue Growth in H1 2025, Launches WuXiHigh 2.0 Platform
Company

WuXi Biologics Reports 16.1% Revenue Growth in H1 2025, Launches WuXiHigh 2.0 Platform

RemeGen's RC148 Granted Breakthrough Therapy Designation for NSCLC Treatment
CompanyDrug

RemeGen’s RC148 Granted Breakthrough Therapy Designation for NSCLC Treatment

Shandong Lukang's CIGB-814 Starts Phase 1 Trial for Rheumatoid Arthritis Treatment
CompanyDrug

Shandong Lukang’s CIGB-814 Starts Phase 1 Trial for Rheumatoid Arthritis Treatment

HutchMed Completes Patient Enrollment for Orpathys and Tagrisso Combination Study
CompanyDrug

HutchMed Completes Patient Enrollment for Orpathys and Tagrisso Combination Study

Sino Biopharmaceutical Reports 10.7% Revenue Growth and 140.2% Profit Surge in H1 2025
Company

Sino Biopharmaceutical Reports 10.7% Revenue Growth and 140.2% Profit Surge in H1 2025

Kangtai Biological Gains NMPA Approval for Trivalent Influenza Vaccine Clinical Trial
CompanyDrug

Kangtai Biological Gains NMPA Approval for Trivalent Influenza Vaccine Clinical Trial

Zhifei Biological's Adult and Adolescent DTaP Vaccine Gains NMPA Trial Approval
CompanyDrug

Zhifei Biological’s Adult and Adolescent DTaP Vaccine Gains NMPA Trial Approval

RemeGen Inks Licensing Deal With Santen China for RC28-E Eye Disease Drug
CompanyDigital

RemeGen Inks Licensing Deal With Santen China for RC28-E Eye Disease Drug

MicroPort CardioFlow's Alwide Plus Wins EU CE Mark for Heart Valve Procedures
CompanyMedical Device

MicroPort CardioFlow’s Alwide Plus Wins EU CE Mark for Heart Valve Procedures

Mabwell's Innovative CDH17-Targeted ADC 7MW4911 Receives FDA Clinical Trial Approval
CompanyDrug

Mabwell’s Innovative CDH17-Targeted ADC 7MW4911 Receives FDA Clinical Trial Approval

Hengrui Pharma's Hetrombopag Olamine Accepted by NMPA for Chemotherapy-Induced Thrombocytopenia
CompanyDrug

Hengrui Pharma’s Hetrombopag Olamine Accepted by NMPA for Chemotherapy-Induced Thrombocytopenia

WuXi XDC Reports Strong H1 2025 Growth With 62.2% Revenue Increase
Company

WuXi XDC Reports Strong H1 2025 Growth With 62.2% Revenue Increase